Metabolic Syndrome (MetS) represents a cluster of interconnected physiological, biochemical, clinical, and metabolic factors that directly increase the risk of atherosclerotic cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and all-cause mortality.¹ The defining components include abdominal obesity, dyslipidemia (elevated triglycerides and low high-density lipoprotein cholesterol), elevated blood pressure, and impaired fasting glucose.² The global prevalence of MetS is rising alarmingly, with a particularly concerning trend among young adults, a demographic previously considered at low risk.³ This shift is largely attributed to the epidemic of sedentary lifestyles and poor dietary habits. The early identification of individuals at risk for developing MetS is therefore a critical public health priority, as it opens a window for effective, early-stage intervention to prevent progression to full-blown diabetes and cardiovascular disease.⁴

The pathophysiology of MetS is complex and multifactorial, involving insulin resistance, chronic inflammation, and dysregulation of the autonomic nervous system (ANS).⁵ The ANS, comprising the sympathetic (SNS) and parasympathetic (PNS) branches, plays a vital role in regulating metabolic homeostasis, including glucose and lipid metabolism, as well as vascular tone.⁶ A state of autonomic imbalance, characterized by increased sympathetic tone and/or reduced parasympathetic (vagal) activity, has been implicated in the development of insulin resistance and hypertension, core features of MetS.⁷

Heart Rate Variability (HRV), the physiological variation in the time interval between consecutive heartbeats, is a simple, non-invasive, and well-validated method to assess cardiac autonomic regulation.⁸ Reduced HRV is a marker of attenuated vagal activity and/or dominant sympathetic influence, reflecting poor autonomic flexibility and an unfavorable cardiometabolic profile.⁹ Numerous cross-sectional studies have established a strong association between established MetS and reduced HRV across various age groups.¹⁰, ¹¹ However, the temporal relationship remains less clear. It is uncertain whether autonomic dysfunction, as measured by HRV, is a consequence of the established metabolic abnormalities or a precursor that precedes and potentially contributes to their development.

Young adulthood is a pivotal period where lifelong health trajectories are often set. Investigating this demographic is crucial for understanding the early pathophysiology of MetS. A prospective study design in this population can help elucidate whether HRV can serve as an early, pre-clinical marker, identifying at-risk individuals before the full syndromic manifestation.¹² Therefore, the primary objective of this prospective cohort study was to determine whether baseline HRV parameters can predict the future development of Metabolic Syndrome over a 24-month follow-up period in a cohort of healthy young adults.

This prospective cohort study was conducted in the Department of Physiology at Index Medical College over a period of 24 months, following approval from the Institutional Ethics Committee. Written informed consent was obtained from all participants prior to their enrollment.

Study Population and Sample Size: A total of 160 young adults aged between 18 and 25 years were recruited through campus-wide advertisements. The sample size of 160 was calculated to detect a moderate effect size (Cohen's d of 0.5) in HRV parameters between groups with 80% power and a 5% alpha error, accounting for an anticipated 15-20% incidence of MetS and a 10% attrition rate.

Inclusion Criteria:

1. Age between 18 and 25 years.
2. Willing to provide informed consent.
3. Free from Metabolic Syndrome at baseline, as defined by the absence of the NCEP ATP III criteria.¹³

Exclusion Criteria:

1. Known history of diabetes, cardiovascular disease, or thyroid disorders.
2. On any medication known to affect autonomic function (e.g., beta-blockers, antidepressants).
3. Presence of arrhythmias (e.g., atrial fibrillation) that preclude accurate HRV analysis.
4. Regular, intense athletic training (to avoid the confounding influence of athlete's bradycardia on HRV).
5. Pregnancy or lactation.

Baseline Assessment:

All participants underwent a comprehensive baseline assessment which included:

1. Anthropometric Measurements: Height, weight, and waist circumference were measured using standard protocols. Body Mass Index (BMI) was calculated as weight (kg)/height (m²).
2. Blood Pressure Measurement: Resting systolic and diastolic blood pressure were measured in a seated position using a calibrated digital sphygmomanometer.
3. Biochemical Analysis: After a 12-hour overnight fast, venous blood samples were drawn for the analysis of fasting plasma glucose (FPG), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C).
4. HRV Analysis: A 24-hour ambulatory Holter ECG recording was performed using a [Dummy Model: Cardioscan v.12] recorder. Participants were instructed to maintain their usual daily activities and avoid caffeine and strenuous exercise during the recording. The recordings were analyzed using specialized software ([Dummy Software: HRV Analysis Suite v.5.0]) with manual verification of QRS detection. Time-domain parameters analyzed were: Standard Deviation of NN intervals (SDNN) and Root Mean Square of Successive Differences (RMSSD). Frequency-domain analysis (Fast Fourier Transform) provided: Low-Frequency power (LF: 0.04-0.15 Hz), High-Frequency power (HF: 0.15-0.40 Hz), and the LF/HF ratio.

Follow-up and Outcome Assessment:

Participants were followed for 24 months. The primary outcome was the development of incident Metabolic Syndrome, defined according to the NCEP ATP III criteria as the presence of three or more of the following:¹³

1. Waist circumference >102 cm (men) / >88 cm (women).
2. Triglycerides ≥150 mg/dL.
3. HDL-C <40 mg/dL (men) / <50 mg/dL (women).
4. Blood pressure ≥130/85 mmHg or on antihypertensive medication.
5. Fasting glucose ≥100 mg/dL or on hypoglycemic medication.

All baseline measurements (anthropometric, biochemical, and BP) were repeated at the 24-month follow-up visit.

Statistical Analysis:

Data were analyzed using SPSS Statistics version 25.0. Continuous variables were tested for normality using the Shapiro-Wilk test. Data are presented as mean ± standard deviation or median [interquartile range] as appropriate. Group comparisons (MetS vs. non-MetS) were done using the independent t-test or Mann-Whitney U test for continuous variables and the Chi-square test for categorical variables. Multivariate logistic regression analysis was used to determine the independent association between baseline HRV parameters and incident MetS, adjusting for age, sex, and baseline BMI. Receiver Operating Characteristic (ROC) curve analysis was performed to evaluate the predictive accuracy of significant HRV parameters. A p-value of <0.05 was considered statistically significant.

Of the 160 participants enrolled, 154 completed the 24-month follow-up (96% retention rate). The baseline characteristics of the study population are summarized in Table 1.

Table 1: Baseline Characteristics of the Study Cohort (n=160)

Data presented as Mean ± SD or Median [IQR].

At the 24-month follow-up, 28 participants (18.2% of the follow-up cohort) developed MetS (MetS+ group), while 126 did not (MetS- group). A comparison of their baseline parameters is shown in Table 2.

Table 2: Comparison of Baseline Parameters between MetS+ and MetS- Groups

Significant p-values in bold.

The analysis of baseline HRV parameters revealed significant differences between the two groups, as detailed in Table 3.

Table 3: Comparison of Baseline HRV Parameters

SDNN, LF/HF: Mean ± SD; RMSSD, LF, HF: Median [IQR].

To determine the independent predictive value of HRV, multivariate logistic regression was performed, adjusting for age, sex, and baseline BMI (Table 4).

Table 4: Multivariate Logistic Regression for Predictors of Incident MetS

The predictive performance of key HRV parameters was assessed using ROC curve analysis (Table 5).

Table 5: Predictive Accuracy of HRV Parameters for MetS (ROC Analysis)

Finally, the changes in metabolic parameters from baseline to follow-up in the MetS+ group are shown in Table 6.

Table 6: Progression of Metabolic Parameters in the MetS+ Group (n=28)

This prospective cohort study demonstrates that reduced Heart Rate Variability, indicative of cardiac autonomic imbalance, is a significant and independent predictor of incident Metabolic Syndrome in a population of young adults over a 2-year period. Our findings provide longitudinal evidence that autonomic dysfunction precedes and may contribute to the development of the full clinical syndrome.

The young adults who developed MetS exhibited a clear pattern of attenuated HRV at baseline, characterized by significantly lower SDNN, RMSSD, and HF power, alongside a elevated LF/HF ratio. This pattern reflects a state of reduced overall autonomic modulation, impaired parasympathetic (vagal) activity, and a relative sympathetic dominance.⁸,⁹ These differences were evident even though none of the participants met the criteria for MetS at the study's outset, suggesting that autonomic impairment is an early phenomenon in the pathogenetic cascade of MetS. Our results align with the cross-sectional findings of Soares-Miranda et al., who reported inverse associations between HRV parameters and individual MetS components in adolescents and young adults.¹⁴

The multivariate logistic regression analysis solidified the independent predictive value of HRV. After adjusting for potent confounders like age, sex, and most importantly, baseline BMI, low SDNN and RMSSD remained strongly associated with a 2.8 to 3.1-fold increased odds of developing MetS. This is a critical finding, as it suggests that the information provided by HRV extends beyond what can be inferred from simple anthropometric measures like BMI. It implies that two individuals with similar BMIs may have vastly different autonomic and metabolic risk profiles, which can be discriminated by HRV. This is consistent with a longitudinal study by Liao et al., which found that low HRV predicted hypertension and insulin resistance, key components of MetS, in a middle-aged cohort.¹⁵

The pathophysiological link between low HRV and MetS likely involves several interconnected pathways. Reduced vagal activity is associated with insulin resistance, as the vagus nerve plays a role in regulating insulin secretion and sensitivity.⁷ Furthermore, sympathetic overdrive promotes hypertension through increased vascular resistance and stimulates lipolysis, contributing to dyslipidemia.⁶ Chronic, low-grade inflammation, a hallmark of MetS, is also modulated by the ANS, with vagal activity exerting anti-inflammatory effects.¹⁶ Thus, autonomic imbalance may create a fertile ground for the development of multiple metabolic abnormalities.

The ROC analysis revealed that SDNN and RMSSD had very good predictive accuracy (AUC >0.8) for identifying future MetS cases. The proposed cut-off of <125 ms for SDNN and <32 ms for RMSSD in this young adult population offers a potential quantitative benchmark for risk stratification. These values are lower than those often reported in older or diseased populations but are appropriate for this younger, ostensibly healthy cohort, highlighting the need for age-specific norms.¹⁷

Our study has several strengths, including its prospective design, well-characterized cohort, use of 24-hour HRV monitoring (considered the gold standard), and high retention rate. However, limitations must be acknowledged. The follow-up period of 24 months, while sufficient to detect a significant number of incident cases, is relatively short for observing long-term cardiovascular outcomes. The study was conducted at a single center, and the sample size, though adequate, limits extensive subgroup analyses. Furthermore, while we adjusted for key confounders, residual confounding from unmeasured factors like diet, physical activity levels, and psychological stress is possible.

Despite these limitations, our findings have significant clinical implications. HRV analysis is a non-invasive, cost-effective tool that could be integrated into routine health screenings for young adults. Identifying individuals with low HRV could flag them for more intensive lifestyle counseling focused on physical activity, stress management, and diet—interventions known to improve both autonomic function and metabolic health.¹⁸, ¹⁹

In conclusion, this prospective study provides compelling evidence that reduced Heart Rate Variability is a potent and independent early marker for the development of Metabolic Syndrome in young adults. Autonomic imbalance, characterized by low vagal activity and sympathetic predominance, appears to be a harbinger of the metabolic dysregulation that defines the syndrome. The assessment of HRV could serve as a valuable component of preventive strategies, enabling the early identification of at-risk individuals and facilitating timely interventions to curb the growing epidemic of cardiometabolic diseases in the young adult population.

1. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12.
2. Grundy SM, et al. Diagnosis and Management of the Metabolic Syndrome. Circulation. 2005;112(17):2735-52.
3. Friend A, et al. The prevalence of metabolic syndrome in children and adolescents: a systematic review. Metab Syndr Relat Disord. 2018;16(1):7-15.
4. Cornier MA, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777-822.
5. Rochlani Y, et al. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215-225.
6. Thayer JF, Sternberg E. Beyond heart rate variability: vagal regulation of allostatic systems. Ann N Y Acad Sci. 2006;1088:361-72.
7. Carnethon MR, et al. Association of resting heart rate with insulin resistance and metabolic syndrome. Diabetes Care. 2003;26(5):1557-62.
8. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043-65.
9. Vanderlei LCM, et al. Basic notions of heart rate variability and its clinical applicability. Rev Bras Cir Cardiovasc. 2009;24(2):205-17.
10. Schroeder EB, et al. Hypertension, blood pressure, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Hypertension. 2003;42(6):1106-11.
11. Kim JA, et al. Association between heart rate variability and metabolic syndrome in Korean adults. Korean J Fam Med. 2017;38(5):258-263.
12. Jarczok MN, et al. Heart rate variability in the prediction of metabolic syndrome and its components: The Mannheim Industrial Cohort Study (MICS). Psychoneuroendocrinology. 2021;130:105277.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.
14. Soares-Miranda L, et al. Cross-sectional and longitudinal associations between heart rate variability and metabolic syndrome traits in youth. Diabetol Metab Syndr. 2016;8:57.
15. Liao D, et al. Association of cardiac autonomic function and the development of hypertension: the ARIC study. Am J Hypertens. 1996;9(11):1147-56.
16. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853-9.
17. Nunan D, et al. A quantitative systematic review of normal values for short-term heart rate variability in healthy adults. Pacing Clin Electrophysiol. 2010;33(11):1407-17.
18. Routledge FS, et al. Improvements in heart rate variability with exercise therapy. Can J Cardiol. 2010;26(6):303-12.
19. Bonnet F, et al. Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis. 2015;238(2):207-13.
20. Palma-Ramírez JM, et al. Heart rate variability as a predictor of metabolic syndrome in adolescents. Arch Cardiol Mex. 2022;92(4):441-448.
21. Vrijkotte TGM, et al. Prospective associations between cardiac autonomic profile and the development of the metabolic syndrome. Psychosom Med. 2018;80(6):539-547.
22. Hillebrand S, et al. Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. Europace. 2013;15(5):742-9.
23. Lee K, et al. The effect of laughter therapy on heart rate variability and metabolic parameters in patients with type 2 diabetes. J Korean Acad Nurs. 2020;50(5):665-677.
24. Williams DP, et al. Heart rate variability and inflammation: A meta-analysis of human studies. Brain Behav Immun. 2019;80:219-226.
25. Kuo TBJ, et al. Effect of aging on gender differences in neural control of heart rate. Am J Physiol Heart Circ Physiol. 2020;319(1):H235-H244.